Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression

Authors

  • Magdalena Kozyra Student Research Group of Applied Psychology, Medical University of Lublin
  • Patryk Zimnicki Student Research Group of Applied Psychology, Medical University of Lublin
  • Natalia Śmiech Student Research Group of Applied Psychology, Medical University of Lublin
  • Justyna Kaczerska Student Research Group of Applied Psychology, Medical University of Lublin
  • Martyna Nowińska Student Research Group of Applied Psychology, Medical University of Lublin
  • Joanna Milanowska Department of Applied Psychology, Medical University of Lublin

DOI:

https://doi.org/10.12775/JEHS.2020.10.08.010

Keywords

Rheumatoid Arthritis, Disease-modifying antirheumatic drugs, depression

Abstract

Introduction: There are similarities in the level of cytokines in Rheumatoid Arthritis (RA) and depression. That is why, during usage of Disease-modifying antirheumatic drugs (DMARDs) which modulate the the level of cytokines may influence both depression and RA The aim of the study: The aim of this article is to find out in what way do the DMARDs influence the depression. Material and method: The research of the scientific articles was made on a database of PubMed and Google Scholar. Description of the state of knowledge: The results show, that most of the DMARDs may decrease the level of depression what is connected with the way of how these medicines influence the level of cytokinese. There are some exceptions such as Chloroquine and anakinra which will increase the probability of depression and there is adalimumab where the is case report which presents one case of appearance of depression after taking this medicine. Summary: This article gathers scientific research on the influence of DMARDs on depression. It shows the mechanisms, and possible ways in which these medicins influence both RA and depression. For some of the DMARDs there are no scientific articles which would include their influence on depression and it might be the way of further researches.

References

Bernaras E, Jaureguizar J, Garaigordobil M. Child and Adolescent Depression: A Review of Theories, Evaluation Instruments, Prevention Programs, and Treatments. Front Psychol. 2019 Mar 20;10:543. doi: 10.3389/fpsyg.2019.00543. PMID: 30949092; PMCID: PMC6435492.

Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014 May;140(3):774-815. doi: 10.1037/a0035302. Epub 2014 Jan 13. PMID: 24417575; PMCID: PMC4006295.

Möller B, Kollert F, Sculean A, Villiger PM. Infectious Triggers in Periodontitis and the Gut in Rheumatoid Arthritis (RA): A Complex Story About Association and Causality. Front Immunol. 2020 Jun 3;11:1108. doi: 10.3389/fimmu.2020.01108. PMID: 32582191; PMCID: PMC7283532.

Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017 Feb;31(1):3-18. doi: 10.1016/j.berh.2017.08.003. Epub 2017 Sep 18. PMID: 29221595; PMCID: PMC5726551.

Renata Budzyńska, Helena Zakliczyńska, Methotrexate in the treatment of the patients with rheumatoid arthritis, Postepy Hig Med Dosw (online), 2004; 58: 108–117

Baza Leków. Leflunomid - Medycyna Praktyczna: opis, ceny, refundacja.

https://www.mp.pl/pacjent/leki/subst.html?id=4321.

“Baza Leków.” Medycyna Praktyczna: opis, ceny, refundacja.

https://www.mp.pl/pacjent/leki/leki/subst.html?id=737.

Schrezenmeier E, Dörner T Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat Rev Rheumatol. 2020 Feb 7, PMID: 32034323

Culy C.R., Keating G.M.: Etanercept. An updated review of its use in rhaumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs, 2002, 62(17): 2493.

Markham., Lamb H.M.: Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs, 2000, 59(6): 1341.

Anakinira, LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-2017 Jul 5. PMID: 31643927

E C Keystone, M C Genovese, L Klareskog, E C Hsia, S T Hall, P C Miranda, J Pazdur, S-C Bae, W Palmer, J Zrubek, M Wiekowski, S Visvanathan, Z Wu, M U Rahman; Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Edward Keystone, Désireé Van Der Heijde, David Mason Jr., Robert Landewé, Ronald Van Vollenhoven, Bernard Combe, Paul Emery, Vibeke Strand, Philip Mease, Chintu Desai, Karel Pavelka, Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study, 30 October 2008

Baza Leków. https://www.mp.pl/pacjent/leki/leki/subst.html?id=4768.

Małgorzata Tłustochowicz, Rituximab: the role in the treatment of rheumatoid arthritis Reumatologia 2011; 49, 1: 55–61

Piotr Wiland, Bożena Kowalewska, Eliza Roszkowska, Jacek Szechiński Review paper The role of abatacept in the treatment of rheumatoid arthritis, Reumatologia 2007; 45, 4: 205–214

Murphy LB, Sacks JJ, Brady TJ, Hootman JM, Chapman DP. Anxiety and depression among US adults with arthritis: prevalence and correlates. Arthritis Care Res (Hoboken). 2012 Jul;64(7):968-76. doi: 10.1002/acr.21685.

Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford). 2011 Feb;50(2):401-9. doi: 10.1093/rheumatology/keq327.

Lotrich FE. Inflammatory cytokine-associated depression. Brain Res. 2015 Aug 18;1617:113-25. doi: 10.1016/j.brainres.2014.06.032.

Wakabayashi C, Numakawa T, Odaka H, Ooshima Y, Kiyama Y, Manabe T, Kunugi H, Iwakura Y. IL-1 receptor-antagonist (IL-1Ra) knockout mice show anxiety-like behavior by aging. Neurosci Lett. 2015 Jul 10;599:20-5. doi: 10.1016/j.neulet.2015.05.019

Ovaskainen Y, Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. Psychiatry Res. 2009 May 15;167(1-2):73-9. doi: 10.1016/j.psychres.2007.12.004

Milaneschi Y, Corsi AM, Penninx BW, Bandinelli S, Guralnik JM, Ferrucci L. Interleukin-1 receptor antagonist and incident depressive symptoms over 6 years in older persons: the InCHIANTI study. Biol Psychiatry. 2009 Jun 1;65(11):973-8. doi: 10.1016/j.biopsych.2008.11.011

Mazarati AM, Pineda E, Shin D, Tio D, Taylor AN, Sankar R. Comorbidity between epilepsy and depression: role of hippocampal interleukin-1beta. Neurobiol Dis. 2010 Feb;37(2):461-7. doi: 10.1016/j.nbd.2009.11.001

Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016 Dec;21(12):1696-1709. doi: 10.1038/mp.2016.3

Huang KW, Wu MK, Hung YY. Elevated TNIP3 mRNA Expression in TNF-α-Secreting Cells from Patients with Major Depressive Disorder. Neuroimmunomodulation. 2019;26(3):153-158. doi: 10.1159/000501083

Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec;103(12):3132-41. doi: 10.1111/j.1572-0241.2008.02175.x

Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol. 2010 May;62(5):812-8.Doi:10.1016/j.jaad.2009.07.022

Jafri F, Sammut A. A rare case of suicidal ideation related to Adalimumab use. Open Access Rheumatol. 2018 Aug 17;10:113-115. doi: 10.2147/OARRR.S168559

Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Baune BT. Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology. 2015 Jan;40(2):502-12. doi: 10.1038/npp.2014.199.

Ng KJ, Huang KY, Tung CH, Hsu BB, Wu CH, Lu MC, Lai NS. Risk factors, including different biologics, associated with depression and anxiety in patients with rheumatoid arthritis: a cross-sectional observational study. Clin Rheumatol. 2019 Dec 10. doi: 10.1007/s10067-019-04820-x

Miwa Y, Isojima S Saito M, Ikari Y, Kobuna M, Hayashi T, Takahashi R, Kasama T, Hosaka M, Sanada K. Comparative Study of Infliximab Therapy and Methotrexate Monotherapy to Improve the Clinical Effect in Rheumatoid Arthritis Patients. Intern Med. 2016;55(18):2581-5. doi: 10.2169/internalmedicine.55.6872.

Miwa Y1, Nishimi A1, Nishimi S1, Saito M1, Tokunaga T1, Yanai R1, Takahashi R1, Wakabayashi K1, Kasama T1, Hosaka M2. Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone. Eur J Rheumatol. 2014 Dec;1(4):147-149.

Choy EHS, Calabrese LH. Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (Oxford). 2018 Nov 1;57(11):1885-1895. doi: 10.1093/rheumatology/kex391.

Corominas H, Alegre C, Narváez J, Fernández-Cid CM, Torrente-Segarra V, Gómez MR, Pan FM, Morlà RM, Martínez FJR, Gómez-Centeno A, Ares LL, Molina RG, González-Albo SP, Dalmau-Carolà J, Pérez-García C, Álvarez CB, Ercole L, Terrancle MÁ; ACT-AXIS Study Group. Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumab: ACT-AXIS study. Medicine (Baltimore). 2019 Jun;98(26):e15947. doi: 10.1097/MD.0000000000015947.

Maes M1, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets. 2014 May;18(5):495-512. doi: 10.1517/14728222.2014.888417.

Mohd Ashari NS, Mohamed Sanusi SNF, Mohd Yasin MA, Che Hussin CM, Wong KK, Shafei MN. Major depressive disorder patients on antidepressant treatments display higher number of regulatory T cells. Malays J Pathol. 2019 Aug;41(2):169-176. PMID: 31427552.

Pinho de Oliveira Ribeiro N, Rafael de Mello Schier A, Ornelas AC, Pinho de Oliveira CM, Nardi AE, Silva AC. Anxiety, depression and suicidal ideation in patients with rheumatoid arthritis in use of methotrexate, hydroxychloroquine, leflunomide and biological drugs. Compr Psychiatry. 2013 Nov;54(8):1185-9. doi: 10.1016/j.comppsych.2013.05.010

Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Symmons DPM; RAMS Co-Investigators, Barton A, Verstappen SMM. Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). Arthritis Res Ther. 2018 Jul 13;20(1):147. doi: 10.1186/s13075-018-1645-5.

Bhat T, Coughlin CC. Mood changes with methotrexate therapy for dermatologic disease. Pediatr Dermatol. 2018 Mar;35(2):253-254. doi: 10.1111/pde.13406.

Petzer JP, Petzer A. Leflunomide, a Reversible Monoamine Oxidase Inhibitor. Cent Nerv Syst Agents Med Chem. 2016;16(2):112-9.

Liu J, Wang Y, Huang C, Xu J, Li Z, Xu L, He L, Sun Y, Wang Y, Xu S, Zhao P, Mao T, Tan B, Zhu F, Zhang P, Fang L. Efficacy and safety of Xinfeng capsule in patients with rheumatoid arthritis: a multi-center parallel-group double-blind randomized controlled trial. J Tradit Chin Med. 2015 Oct;35(5):487-98.

Imai F, Suzuki T, Ishibashi T, Dohi Y. Effect of sulfasalazine on B cells. Clin Exp Rheumatol. 1991 May-Jun;9(3):259-64.

Nashed MG, Ungard RG, Young K, Zacal NJ, Seidlitz EP, Fazzari J, Frey BN, Singh G. Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression. Sci Rep. 2017 Jan 25;7:41382. doi: 10.1038/srep41382.

Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford). 2006 Jun;45(6):703-10.

Mohan D, Mohandas E, Rajat R. Chloroquine psychosis: a chemical psychosis? J Natl Med Assoc. 1981 Nov;73(11):1073-6.

Krishnadas R, Krishnadas R, Cavanagh J. Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: a case report and review of the literature. J Med Case Rep. 2011 Mar 19;5:112. doi: 10.1186/1752-1947-5-112.

Das EM, Mohan D. Chloroquine-related depression. Indian J Psychiatry. 1981 Apr;23(2):184-5.

Downloads

Published

2020-08-01

How to Cite

1.
KOZYRA, Magdalena, ZIMNICKI, Patryk, ŚMIECH, Natalia, KACZERSKA, Justyna, NOWIŃSKA, Martyna and MILANOWSKA, Joanna. Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression. Journal of Education, Health and Sport. Online. 1 August 2020. Vol. 10, no. 8, pp. 81-92. [Accessed 27 November 2024]. DOI 10.12775/JEHS.2020.10.08.010.

Issue

Vol. 10 No. 8 (2020)

Section

Review Articles

License

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 650
Number of citations: 0